Whether it is new and groundbreaking research results, university topics or events – in our press releases you can find everything you need to know about the happenings at 51ÁÔÆæ. To subscribe, just send an email to ott@pvw.uni-frankfurt.de
Theodor-W.-Adorno Platz 1
60323 Frankfurt
presse@uni-frankfurt.de
International research team led by 51ÁÔÆæ debunks concept popular for decades
Contrary to a concept propagated for almost 30 years, specialized pro-resolving lipid mediators, which our body forms from polyunsaturated omega-3 fatty acids, evidently do not actively stop inflammation. Although such resolvins or lipoxins can be produced under laboratory conditions, it is highly probably that they play no physiological role whatsoever. This is corroborated by a review undertaken by an international research team led by Professor Dieter Steinhilber from 51ÁÔÆæ, Frankfurt. The starting point for this work, which has caused quite a stir in the academic community, was experimental findings by the Research Training Group “Resolution of inflammation – Mediators, signalling and therapeutic options" at 51ÁÔÆæ.
FRANKFURT. Inflammation
is the result of an active defence reaction by our immune system. It mostly disappears
by itself. It was once assumed to be a passive process because the immune cells
involved, having done their work, gradually die off or migrate. Today, we know
that our body also actively controls the resolution of inflammation. To this
end, certain cells of the innate immune system, known as M1 macrophages, which are
pro-inflammatory and in the first instance serve as a defence mechanism,
transform into M2 macrophages, which are anti-inflammatory and primarily help
to heal wounds.
In the past, the formation of specialized
pro-resolving lipid mediators (SPMs) was considered an important molecular
effect of this transformation. Since their discovery in 1984, they have given
an ever-growing group of “resolutionists" worldwide reason to hope that it
would one day be possible to intervene therapeutically in inflammatory
processes by means of synthetic “inflammation resolvers" (resolvins).
The drugs against inflammation and its
symptoms that are currently available – such as acetylsalicylic acid and COX-2
inhibitors – act, by contrast, as antagonists to certain arachidonic acid
metabolism reactions, which generate pro-inflammatory tissue hormones. These
include thromboxane and prostaglandins on the one hand and leukotrienes on the
other. Only two metabolism steps away from arachidonic acid, those SPMs are also
produced to which an anti-inflammatory effect has so far been attributed.
Indeed, a doctoral thesis in the Research
Training Group “Resolution of inflammation – Mediators, signalling and
therapeutic options" established at 51ÁÔÆæ in 2017 showed that the anti-inflammatory
macrophages form the two enzymes needed to produce SPMs. However, only under
non-physiological conditions – the researchers added stimulators that increased
the calcium permeability of the macrophage membrane (ionophores) – could tiny
amounts of SPMs be detected. Even when, as another study demonstrated,
pre-treated substrates of these enzymes were added to cell cultures of certain
white blood cells (neutrophilic leukocytes), these substrates were hardly
converted to lipoxins and resolvins.
Further suspicion was triggered by earlier
work on SPM receptors by Professor Stefan Offermanns, who, like Professor
Dieter Steinhilber, is project leader in the Collaborative Research Centre “Signalling
by fatty acid derivatives and sphingolipids in health and disease" hosted by
51ÁÔÆæ. In his study, no effect of lipoxin A via the corresponding G
protein-coupled receptor could be identified. Lipid mediators transmit their
signals via these receptors. Moreover, in the blood plasma of healthy volunteers,
SPMs could at best be found in the single-digit picogramme range, even when
using the most sensitive and selective methods (coupling of chromatography and
mass spectrometry).
On the basis of these findings,
Steinhilber's research team combed through all the papers on SPMs published so
far. This review endorsed their dismantling of the SPM concept: human
leukocytes, to which macrophages also belong, can at best synthesize small
amounts of SPMs. These amounts are so tiny that they cannot be reliably
quantified even with state-of-the-art analytics. There is no correlation
between SPM synthesis and the resolution of an inflammatory reaction nor with a
targeted intake of polyunsaturated omega-3 fatty acids. To date, there is no
valid evidence of functional SPM receptors.
“Insiders have known for a long time that
the SPM concept was questionable," says Steinhilber. “But until now no one has
taken the trouble to gather all the doubts together." There had to be another
mechanism of active inflammation resolution, he says. “Because the transformation
of pro-inflammatory M1 macrophages into anti-inflammatory M2 macrophages
clearly goes hand in hand with a change in the lipid and cytokine profile."
“The search for the molecular signals that
our body uses to actively prevent excessive or chronic inflammation continues
to be exciting," says Professor Bernhard Brüne, Vice President of Goethe
University and spokesperson for the Research Training Group. “It's a source of
motivation for our future research."
Publication:
Nils Helge Schebb, Hartmut Kühn, Astrid S.
Kahnt, Katharina M. Rund, Valerie B. O'Donnell, Nicolas Flamand, Marc
Peters-Golden, Per-Johan Jakobsson, Karsten H. Weylandt, Nadine Rohwer, Robert
C. Murphy, Gerd Geisslinger, Garret A. FitzGerald, Julien Hanson, Claes
Dahlgren, Mohamad Wessam Alnouri, Stefan Offermanns, Dieter Steinhilber: Formation, Signalling and Occurrence of Specialized
Pro-Resolving Lipid Mediators – What is the Evidence so far? Frontiers in Pharmacology (2022)
Further
information:
Professor Dieter Steinhilber
Institute of Pharmaceutical Chemistry
51ÁÔÆæ Frankfurt, Germany
Tel.: +49 (0)69 798-29324
Steinhilber@em.uni-frankfurt.de